6505--Radiopharmaceuticals for Positron Emitting Tomography (PET) Imaging
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the George E. Wahlen VA Medical Center in Salt Lake City, Utah, is soliciting quotes for Radiopharmaceuticals for Positron Emitting Tomography (PET) Imaging. This is a Total Small Business Set-Aside opportunity for a firm-fixed-price contract. The primary requirement is for F-18 Piflufolastat (or equivalent) and related supplies. Quotes are due by March 20, 2026, at 5:00 PM MT.
Scope of Work
The contractor will provide unit dose radiopharmaceuticals, radioactive sources, and supplies for diagnostic imaging and quality assurance. Key responsibilities include:
- Routine weekday deliveries (Monday-Friday, by 8:00 AM MST) to the Nuclear Medicine Department.
- Supplying F-18 Piflufolastat (Pylarify) or an equivalent product.
- Providing radioactive sources for quality assurance/control.
- Ensuring radiopharmaceuticals are prepared by a certified nuclear medicine pharmacist and comply with USP 797 and 825 guidelines.
- Delivering urgent requests within two (2) hours during normal working hours.
- Complying with all federal and state regulations for shipping radioactive materials.
- Providing radiation safety equipment, patient education materials, and safety signs.
Contract Details
- Contract Type: Firm-Fixed-Price
- Set-Aside: Total Small Business (NAICS 325412, 1300-employee size standard)
- Period of Performance: A base year (April 1, 2026 – March 31, 2027) with three one-year option periods, not to exceed a total of three years.
- Place of Performance: Nuclear Medicine Department, VA Salt Lake City Health Care System, Salt Lake City, UT.
- Prohibitions: No gray market or remanufactured items. Offerors must be an OEM, authorized dealer, distributor, or reseller, verified by an OEM authorization letter.
- Award Basis: All or Nothing.
Submission Requirements
Offerors must submit quotes via email to heather.chase2@va.gov by March 20, 2026, 5:00 PM MT. Submissions must include:
- Volume I: Technical capability demonstrating compliance with the Statement of Work.
- Volume II: Completed Price Schedule (Attachment 2), including pricing for the base year and all option years for Piflufolastat F18 and cancellation fees.
- Volume III: Copies of current and unrevoked Utah Professional, Nuclear Regulatory Commission (NRC), and/or Federal Drug Administration (FDA) licenses.
- Volume IV: Completed RFO 52.225-2 Buy American Certificate (Attachment 3).
- Questions are due by March 16, 2026, 12:00 PM MT.
Evaluation Factors
The Government will use a comparative evaluation process, considering:
- Technical capability or quality to meet the Government's requirements.
- Price.
- Licenses (validity and status, including any adverse actions).
- RFO 52.225-2 Buy American Certificate (completeness and compliance). The Government may select an offer that provides additional benefits beyond minimum requirements, even if not the lowest price.